Abstract
Introduction: Malignant hyperthermia (MH) is a life-threatening pharmacogenetic skeletal muscle disorder resulting in increased myoplasmic calcium concentrations leading to sustained muscle contraction. In cases susceptible to MH, a total intravenous intravenous anaesthesia (TIVA) approach is employed to avoid the use of MH triggering agents namely volatile anaesthetics and suxamethonium. Case presentation: In this case report, we present a seven-month-old male infant with MH susceptibility that was scheduled for a rectal biopsy under general anaesthesia. The patient was managed according to MH guidelines and paediatrics dosing schemes for TIVA; using propofol and remifentanil as an adjuvant. The case was management successfully and uneventfully. Conclusion: MH is a potentially life-threatening disorder, hence following the evidence-based precautions and management of patients with suspected MH is key. Moreover, managing a paediatric patient with MH suspicion often impose additional challenges. In this case report, the perioperative considerations for infants with MH suspicion is discussed. Keywords: Malignant Hyperthermia, Total Intravenous Anaesthesia, Steur propofol infusion scheme.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
